The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.
March 16th 2024
Urinary miR-92a-3p, miR-425-5p, and miR-185-5p were significantly increased in patients with IgAN and were all associated with tubular atrophy/interstitial fibrosis.
New Targets, New Treatments, and New Combinations for the Management of Advanced Prostate Cancer
View More
Medical Crossfire®: Why is PSMA so Effective? To Affinity and Beyond
View More
Clinical ShowCase™ in aHUS: The Application of Complement Inhibitors in Practice
View More
Navigating Newer Approaches to Managing IgA Nephropathy
April 14, 2024
Register Now!
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Evaluating the Recent Advancements in Chronic Kidney Disease Treatment: A Case-Based Approach to Managing CKD and Related Comorbidities
View More
Expert Illustrations and Commentaries™: Emerging Therapies and Treatment Strategies to Improve Care for Your Patients with Anemia in CKD
View More
The Nephrology Nurse’s Role in Optimizing Outcomes for Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Community Practice Connections: 7th Annual School of Nursing Oncology™
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Bridging the Care Gap in Anemia in CKD: A Comprehensive Guide to Enhancing Patient Care
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: How Do the Experts Select and Sequence Therapies to Optimize Patient Outcomes and Quality of Life in Advanced Prostate Cancer?
View More
7th Annual New York Cardio-Endo-Renal Collaborative (NY CERC)
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
GU Tumor Board®: Real World Strategies to Inform Individualized Care in Renal Cell Carcinoma
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Expert Illustrations & Commentaries™: Exploring the Role of Novel Agents for the Management of IgA Nephropathy
View More
Patient, Provider & Caregiver Connection™: Implementing an Effective Management Plan to Improve Outcomes in IgA Nephropathy
View More
Semaglutide 1.0 mg (Ozempic) Reduced Kidney Events 24% in FLOW Trial
March 5th 2024Novo Nordisk announced topline data from the FLOW trial indicate semaglutide 1.0 mg (Ozempic) was associated with a 24% reduction in risk of kidney disease-related events among individuals with type 2 diabetes and CKD compared to placebo therapy.
Experts' Perspectives: How Lacking Clinical Trial Diversity Impacts Public Health
March 1st 2024This article serves as a landing page for our 3-part series spotlighting how a lack of diversity in clinical trials has had a deleterious downstream effect on real-world care for people of color in the US, with perspective from experts across more than half a dozen specialties.
Clinical, Pathological Distinctions Provide Basis for Differentiating IgAN, IgAVN
February 7th 2024Findings from this retrospective study help address challenges in distinguishing immunoglobulin A nephropathy from immunoglobulin A vasculitis-associated nephritis, overcoming their shared pathogenetic features.
Home-Based Albuminuria Screening Cost-Effective for Preventing Kidney, Cardiovascular Events
February 6th 2024Findings highlight the potential benefits of implementing home-based screening for albuminuria in the general population to reduce the burden of kidney and cardiovascular diseases while maintaining cost-effectiveness.
Hydroxychloroquine, Leflunomide Improve Proteinuria, Renal Function in IgAN
February 5th 2024Hydroxychloroquine and leflunomide were found to be safe and effective for treating IgAN, with study results showing the use of both immunosuppressants in combination with a renin-angiotensin system inhibitor proved most effective in improving proteinuria and stabilizing renal function.
Endocrinology Month in Review: January 2024
January 31st 2024This endocrinology month in review spotlights FDA news, a pair of studies examining cardiovascular and renal risk reduction in type 2 diabetes, results from a subtrial examining testosterone’s effect on fracture risk, and 4 new episodes of diabetes dialgoue
eGFR Based on Creatinine, Cystatin C May Offer Better CKD Threshold for Older Adults
January 31st 2024Low eGFRcr-cys was more strongly and uniformly associated with adverse outcomes compared to low eGFRcr in an older patient population, highlighting the benefit of including cystatin C in GFR estimation.
Patients With Vitiligo, End-Stage Renal Disease Face Greater Risk of Infection
January 30th 2024Vitiligo was significantly associated with an increased risk of bacteremia, cellulitis, and herpes zoster and was more common among those with female sex, Black compared to White race, Hispanic ethnicity, hepatitis C infection, and tobacco use.
SGLT2i Use Linked to Lower Risk of Nephrolithiasis in Patients With Type 2 Diabetes
January 29th 2024Compared to glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors, Use of sodium-glucose cotransporter 2 inhibitors was linked to a decreased risk of nephrolithiasis in patients with type 2 diabetes.
Automated AKI Alert Prompts Change of Care, Shows No Impact on Patient Outcomes
January 26th 2024Use of the electronic AKI alert system led to slight improvements in intervention rates and AKI diagnosis, although kidney function and patient-centered outcomes did not differ from patients receiving usual care.
72-Week Phase 2B ORIGIN Data Highlight Potential Benefit of Atacicept in IgA Nephropathy
January 25th 2024The 72-week open-label extension of the phase 2b ORIGIN trial reveals atacicept's potential as a disease-modifying treatment for IgA nephropathy, showing eGFR stabilization and improvements in key indicators
Patients with IgA Nephropathy May Not Be Receiving Optimal Supportive Care
January 24th 2024Results called attention to suboptimal blood pressure and proteinuria control as well as a lack of maximal RAASI dosing in a cohort of adult patients with IgAN from the Cure Glomerulonephropathy Network study.